Patent intelligence · EP
EP 1311248
TRANSDERMALES THERAPEUTISCHES SYSTEM ZUR BEHANDLUNG DES RESTLESS-LEGS-SYNDROMS
TRANSDERMALES THERAPEUTISCHES SYSTEM ZUR BEHANDLUNG DES RESTLESS-LEGS-SYNDROMS
Patent details — EP 1311248
- Jurisdiction
- EP
- Status
- expired
- Grant date
- May 21, 2003
- Expiration
- May 16, 2023
- Applicant
- NEUROBIOTEC GMBH [DE]
- CPC classes
- A61K 9/ 70 A I, A61K 31/ 48 A I, A61K 31/ 437 A I, A61K 47/ 02 A I
Quick answer
EP 1311248 (TRANSDERMALES THERAPEUTISCHES SYSTEM ZUR BEHANDLUNG DES RESTLESS-LEGS-SYNDROMS) is held by NEUROBIOTEC GMBH [DE]. Status: expired. Granted May 21, 2003. Expires May 16, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- NEUROBIOTEC GMBH [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 70 A I, A61K 31/ 48 A I, A61K 31/ 437 A I, A61K 47/ 02 A I, A61K 47/ 04 A I, A61K 47/ 06 A I
More from NEUROBIOTEC GMBH [DE]
Related pharmaceutical patents in our USPTO index.
-
CA 2626142
SOLUTIONS AQUEUSES STABILISEES DE COMPOSES D'ERGOLINE
granted -
DE 102006048130
Transdermales therapeutisches System mit zweiphasigem Freisetzungsprofil
granted -
IT MI20070164
CEROTTO TRANSDERMICO
granted -
DE 102004006048
Pharmazeutische Kombination aus Gadolinium Komplexen und kolloidalen Biopolymeren und deren Verwendung als kontrastverstärkendes Mittel zur i.v. Injektion bzw. i.v. Infusion in der MR Angiographie
expired -
DE 10341317
Mittel zur transdermalen Applikation
expired -
AU 2002363847
1-ALLYL ERGOT ALKALOID DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF FOR PREVENTING AND TREATING MIGRAINE
expired -
EP 1303278
KOMBINATION EINES TRANSDERMALEN THERAPEUTISCHEN SYSTEMS UND EINER ORALEN UND/ODER PARENTERALEN ZUBEREITUNG ENTHALTEND DOPAMINAGONISTEN ZUR BEHANDLUNG DOPAMINERGER ERKRANKUNGEN
expired
Frequently asked questions
What is US patent 1311248?
EP 1311248 (TRANSDERMALES THERAPEUTISCHES SYSTEM ZUR BEHANDLUNG DES RESTLESS-LEGS-SYNDROMS) is held by NEUROBIOTEC GMBH [DE]. Status: expired. Granted May 21, 2003. Expires May 16, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 1311248?
NEUROBIOTEC GMBH [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.
When does EP 1311248 expire?
Our index shows an expiration date of May 16, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.